NASDAQ · COLL
Healthcare · Drug Manufacturers - Specialty & Generic
$21.87
Up+$0.01 (+0.05%)
Updated Oct 7, 2026, 1:51 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · COLL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
COLL closed at $21.87 after 20 trading sessions, down 6.42% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $22.23 | $22.255 | $21.67 | $21.87 | 975.38K |
| Oct 2, 2026 | $21.97 | $22.38 | $21.64 | $22.02 | 694.06K |
| Oct 1, 2026 | $21.94 | $22.28 | $21.43 | $21.84 | 1M |
| Sep 30, 2026 | $22.14 | $22.33 | $21.82 | $21.82 | 811.56K |
| Sep 29, 2026 | $22.61 | $22.92 | $21.62 | $22.23 | 1.02M |
| Sep 28, 2026 | $22.625 | $23.17 | $22.355 | $22.63 | 687.38K |
| Sep 25, 2026 | $22.58 | $22.9055 | $22.29 | $22.53 | 503.43K |
| Sep 24, 2026 | $22.27 | $22.77 | $21.9004 | $22.64 | 650.12K |
| Sep 23, 2026 | $23.23 | $23.69 | $21.77 | $22.45 | 878.44K |
| Sep 22, 2026 | $23.46 | $23.515 | $22.64 | $22.78 | 808.25K |
| Sep 21, 2026 | $22.78 | $23.23 | $22.505 | $23.04 | 928.27K |
| Sep 18, 2026 | $22.17 | $22.93 | $22.07 | $22.77 | 1.99M |
| Sep 17, 2026 | $22.36 | $22.64 | $22.08 | $22.38 | 707.37K |
| Sep 16, 2026 | $21.84 | $22.80 | $21.68 | $22.19 | 1.15M |
| Sep 15, 2026 | $22.81 | $22.92 | $21.6501 | $21.84 | 954K |
| Sep 14, 2026 | $22.80 | $23.19 | $22.50 | $22.81 | 825.55K |
| Sep 11, 2026 | $23.02 | $23.245 | $22.64 | $22.75 | 661.3K |
| Sep 10, 2026 | $23.38 | $23.45 | $22.72 | $22.92 | 889.1K |
| Sep 9, 2026 | $23.56 | $24.11 | $23.115 | $23.36 | 1.08M |
| Sep 8, 2026 | $23.33 | $23.82 | $23.11 | $23.37 | 1.11M |
The latest Smart Investors Daily articles mentioning COLL.
Company
Market Activity
Research & News
COLL research
Company profile and research snapshot.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 9, 2026 | Truist Securities | Buy | — |
| Aug 19, 2026 | Barclays | Overweight | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Yahoo · Sep 30, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.7% gain over the past six months, beating the S&P 500 by 25.6 percentage points.
Yahoo · Sep 28, 2026
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.
Benzinga · Sep 23, 2026
Oppenheimer analyst Les Sulewski initiates coverage on Collegium Pharmaceutical (NASDAQ:COLL) with a Outperform rating and announces Price Target of $50.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COLL.
